ACE2 and COVID-19: In addition to the lower ACE2 expression in the lungs of elderly patients (Wu and McGoogan, 2020), other characteristics, such as the presence of other comorbidities, immune senescence, or low-grade inflammation associated with aging (inflammaging), could influence COVID-19 outcomes (Franceschi and Campisi, 2014; Fuentes et al., 2017).